Research Overview
Research on perilla oil has most frequently focused on cardiometabolic outcomes, particularly blood lipid regulation in people with hyperlipidemia, along with related biomarkers of vascular inflammation and endothelial function. The provided abstract describes an 8-week intervention in which lipid panels (TG, TC, LDL-C, HDL-C) were measured before and during treatment, and additional assays assessed inflammatory/endothelial injury–related signaling factors. Safety monitoring included liver and kidney function tests and routine blood examinations, reflecting a common emphasis in the literature on both efficacy and tolerability for metabolic risk reduction.
The strongest evidence supported by this abstract is that perilla oil intake is associated with improvements in standard serum lipid measures over a relatively short timeframe (notably reductions in TG, TC, and LDL-C and increases in HDL-C), with statistically significant changes emerging by ~4 weeks and persisting to 8 weeks. The study also reports no detectable adverse effects on hepatic or renal function or routine hematologic parameters over the intervention period, suggesting short-term clinical safety in the studied population. Additionally, the authors conclude that perilla oil may protect endothelial cell function, although the strength of this claim depends on the rigor and specificity of the endothelial/inflammatory endpoints and the study design details (e.g., controls, blinding), which are not provided in the abstract.
Key areas needing more research include higher-quality randomized controlled trials with clear comparator oils/placebo, standardized dosing and composition reporting (e.g., fatty acid profile), and longer follow-up to determine durability of lipid changes and effects on clinical endpoints (e.g., cardiovascular events) rather than biomarkers alone. Further work is also needed to clarify mechanisms (endothelial and inflammatory pathways), identify which patient subgroups benefit most, and evaluate safety and efficacy with chronic use, concomitant lipid-lowering medications, and in broader populations beyond hyperlipidemia (e.g., metabolic syndrome, diabetes, or primary prevention cohorts).
1. What conditions has Perilla Oil been studied for?
Hyperlipidemia (elevated blood lipids): The abstract describes an 8-week clinical evaluation in patients with hyperlipidemia, measuring changes in triglycerides (TG), total cholesterol (TC), LDL-cholesterol (LDL-C), and HDL-cholesterol (HDL-C).
Endothelial dysfunction / vascular inflammation-related markers (as secondary outcomes): The study also assessed “indexes which correlate with inflammation and injury to endothelial cells” using ELISA, implying interest in vascular/endothelial protection in the context of dyslipidemia.
2. Does it work in treating those conditions? Summarize the evidence.
-
Blood lipid improvement in hyperlipidemia: After 56 days of perilla oil treatment, serum TG, TC, and LDL-C “changed significantly,” with differences noted as early as 28 days (P < 0.05). HDL-C showed “statistically significant recovery levels” at both 28 and 56 days.
-
Overall lipid lowering: The abstract states that “plasma lipids levels were significantly lower after 56 days” (P < 0.05), consistent with a lipid-lowering effect over ~8 weeks.
-
Endothelial/inflammatory markers: The authors conclude perilla oil “protects the function of endothelial cells,” but the abstract does not provide specific marker names, effect sizes, or numerical results—so the strength of evidence for endothelial protection cannot be fully assessed from the abstract alone.
-
Limitations based on the abstract: The abstract does not describe randomization, blinding, a placebo/control group, sample size, dose, baseline characteristics, or absolute lipid changes. Without these details, the certainty of causality and the magnitude of benefit are unclear.
3. What health benefits does it have?
Lipid profile improvement: Significant changes in TG, TC, LDL-C after 56 days, with changes detectable by 28 days (P < 0.05).
HDL-C increase (“recovery”): HDL-C improved significantly at 28 and 56 days.
Potential vascular/endothelial support: The study assessed markers related to inflammation and endothelial injury and concludes endothelial function is protected, though specific data are not shown in the abstract.
4. Does it have any downsides or side effects?
-
No major safety signals reported in this abstract: The authors report that regulation of cell signaling factor levels had “no adverse effects” on:
Liver function
Kidney function
Blood routine examinations
-
Limitations of the safety evidence: The abstract does not report the number of participants, adverse event rates, gastrointestinal symptoms, bleeding-related outcomes, or longer-term follow-up. Therefore, rare side effects or longer-term risks cannot be ruled out from this information alone.
5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?
The provided abstract does not report any pharmacogenomic analyses or outcomes stratified by genotype. Therefore:
No direct evidence here that perilla oil is beneficial or harmful for specific genetic variants.
Unknown from this abstract whether genetic differences in lipid metabolism or fatty-acid processing modify response or risk.
References
-
Perilla oil and exercise decrease expressions of tumor necrosis factor-alpha, plasminogen activator inhibitor-1 and highly sensitive C-reactive protein in patients with hyperlipidemia
Minggang Wei, Peihua Xiong, Ling Zhang, Mei Fei, Aiping Chen (2013)
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!